Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils
D Torti, L Trusolino - EMBO molecular medicine, 2011 - embopress.org
A decade has elapsed since the concept of oncogene addiction was first proposed. It
postulates that–despite the diverse array of genetic lesions typical of cancer–some tumours …
postulates that–despite the diverse array of genetic lesions typical of cancer–some tumours …
CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression
RL Brown, LM Reinke, MS Damerow… - The Journal of …, 2011 - Am Soc Clin Investig
Epithelial-mesenchymal transition (EMT) is a tightly regulated process that is critical for
embryogenesis but is abnormally activated during cancer metastasis and recurrence. Here …
embryogenesis but is abnormally activated during cancer metastasis and recurrence. Here …
[HTML][HTML] Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
D Chakravarty, E Santos, M Ryder… - The Journal of …, 2011 - Am Soc Clin Investig
Advanced human thyroid cancers, particularly those that are refractory to treatment with
radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene …
radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene …
A targeted proteomics–based pipeline for verification of biomarkers in plasma
JR Whiteaker, C Lin, J Kennedy, L Hou, M Trute… - Nature …, 2011 - nature.com
High-throughput technologies can now identify hundreds of candidate protein biomarkers for
any disease with relative ease. However, because there are no assays for the majority of …
any disease with relative ease. However, because there are no assays for the majority of …
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms
P Liu, H Cheng, S Santiago, M Raeder, F Zhang… - Nature medicine, 2011 - nature.com
PIK3CA gain-of-function mutations are a common oncogenic event in human malignancy,,,,
making phosphatidylinositol 3-kinase (PI3K) a target for cancer therapy. Despite the promise …
making phosphatidylinositol 3-kinase (PI3K) a target for cancer therapy. Despite the promise …
Choosing a mouse model: experimental biology in context—the utility and limitations of mouse models of breast cancer
AD Borowsky - Cold Spring Harbor perspectives in …, 2011 - cshperspectives.cshlp.org
Genetically engineered mice are critical experimental models for the study of breast cancer
biology. Transgenic mice, employing strong mammary epithelial promoters to drive …
biology. Transgenic mice, employing strong mammary epithelial promoters to drive …
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models
We investigated the potential of in-depth quantitative proteomics to reveal plasma protein
signatures that reflect lung tumor biology. We compared plasma protein profiles of four …
signatures that reflect lung tumor biology. We compared plasma protein profiles of four …
Tumor microenvironment–derived proteins dominate the plasma proteome response during breast cancer induction and progression
SJ Pitteri, KS Kelly-Spratt, KE Gurley, J Kennedy… - Cancer research, 2011 - AACR
Tumor development relies upon essential contributions from the tumor microenvironment
and host immune alterations. These contributions may inform the plasma proteome in a …
and host immune alterations. These contributions may inform the plasma proteome in a …
The normal mammary microenvironment suppresses the tumorigenic phenotype of mouse mammary tumor virus-neu-transformed mammary tumor cells
BW Booth, CA Boulanger, LH Anderson, GH Smith - Oncogene, 2011 - nature.com
The microenvironment of the mammary gland has been shown to exert a deterministic
control over cells from different normal organs during murine mammary gland regeneration …
control over cells from different normal organs during murine mammary gland regeneration …
KRAS mouse models: modeling cancer harboring KRAS mutations
RC O'Hagan, J Heyer - Genes & cancer, 2011 - journals.sagepub.com
KRAS is a potent oncogene and is mutated in about 30% of all human cancers. However,
the biological context of KRAS-dependent oncogenesis is poorly understood. Genetically …
the biological context of KRAS-dependent oncogenesis is poorly understood. Genetically …